Pulse Biosciences (PLSE) Set to Post Quarterly Earnings on Thursday

Key Points

• Pulse Biosciences is expected to report Q3 2026 results after market close on November 5. Analysts forecast a loss of $0.3095 per share and revenue of approximately $0.52 million.
• The company’s previous quarter fell short of expectations, with a $0.36 per-share loss versus the estimated $0.29 loss and revenue of $0.43 million versus the projected $0.53 million.
• Despite mixed analyst views, the stock has risen sharply, trading at $53.67 with a consensus “Moderate Buy” rating and a $60.20 price target. Insiders have also purchased shares, while insiders collectively own 74% of the company.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Pulse Biosciences to post earnings of ($0.3095) per share and revenue of $0.52 million for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The company had revenue of $0.43 million during the quarter, compared to analysts' expectations of $0.53 million. On average, analysts expect Pulse Biosciences to post ($1.34) EPS for the current fiscal year and ($1.41) EPS for the next fiscal year.

Pulse Biosciences Price Performance

NASDAQ:PLSE opened at $53.67 on Thursday. The business has a fifty day simple moving average of $50.82 and a two-hundred day simple moving average of $30.89. Pulse Biosciences has a 1 year low of $12.56 and a 1 year high of $58.90. The company has a market capitalization of $3.80 billion, a P/E ratio of -45.48 and a beta of 1.57.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on PLSE shares. Wall Street Zen upgraded Pulse Biosciences from a "sell" rating to a "hold" rating in a research report on Sunday, September 6th. Oppenheimer boosted their price objective on shares of Pulse Biosciences from $35.00 to $60.00 and gave the company an "outperform" rating in a research report on Tuesday, October 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pulse Biosciences in a research note on Thursday, October 15th. Freedom Capital upgraded shares of Pulse Biosciences to a "strong-buy" rating in a report on Wednesday, September 9th. Finally, Canaccord Genuity Group raised their target price on Pulse Biosciences from $43.00 to $58.00 and gave the stock a "buy" rating in a research note on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Pulse Biosciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $60.20.

Insider Buying and Selling

In other news, COO Liane Teplitsky acquired 1,001 shares of Pulse Biosciences stock in a transaction on Tuesday, September 1st. The stock was acquired at an average cost of $49.95 per share, for a total transaction of $49,999.95. Following the purchase, the chief operating officer owned 4,095 shares in the company, valued at $204,545.25. This trade represents a 32.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have bought 4,095 shares of company stock worth $199,931. Corporate insiders own 74.00% of the company's stock.

About Pulse Biosciences

Pulse Biosciences, Inc NASDAQ: PLSE is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company's principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.